Effects of vitamin D supplementation on risks of delayed relapse or death in patients with cancer and especially in a subgroup of patients with p53-positive cancer

Phase 3

Recruiting

• Conditions: lung cancer, colorectal cancer, liver cancer, gastric cancer, breast cancer, esophageal cancer, panc; cancer, p53-positive cancer; Neoplasms, Tumor Suppressor Protein p53

• Registration Number: JPRN-jRCTs031210460
• Lead Sponsor: Eto Ken

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-11-29
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 1240

Inclusion Criteria

Target disease
I. Cancer types that are expected to be completely cured by surgery (including cases where metastasis can be resected) and have a certain frequency of death from all cancers: lung cancer, colon cancer, liver cancer, gastric cancer, breast cancer, esophageal tract Cancer, pancreatic cancer, head and neck cancer

II. Mainly includes stage I, II, III and some IV. On the other hand, it does not include carcinoma in situ.
Some IV; Include if radical cure = macroscopic resection even in stage IV: Include stage IVA for head and neck cancer, liver metastasis for colorectal cancer, etc. if remission is obtained.
Carcinoma in situ; Endoscopically resected by preoperative diagnosis of carcinoma in situ, but postoperative pathological diagnosis revealed that it was stage I or higher. If complementary surgery is required at this research facility due to referrals, etc., it will be included in the study. The endoscopy facility may be another hospital.

III. Histopathology is major
Lung cancer: invasive adenocarcinoma, squamous carcinoma, adenosquamous carcinoma
Colorectal cancer: Adenocarcinoma (including colorectal cancer but not small intestine cancer)
Liver cancer: Hepatocellular carcinoma
Pancreatic cancer: pancreatic ductal cancer (adenocarcinoma)
Gastric cancer: adenocarcinoma, esophagogastric junction adenocarcinoma (Siewert type III)
Breast cancer: Invasive breast cancer
Esophageal cancer: squamous epithelial cancer, esophagogastric junction adenocarcinoma (Siewert type I, II)
Head and neck cancer: pharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, oral cavity cancer

Selection criteria
(1) Initial cancer patients who fall under the above target diseases (= if multiple cancers, recurrent cancers, invasive cancers occur at other sites and a series of treatments have been completed and less than 5 years have passed, all are excluded).
Invasive cancer: However, those with a history of carcinoma in situ within 5 years or multiple cancers in situ are included in the research target.
(2) Patients scheduled to undergo surgery at the Jikei University Hospital Surgery / Otorhinolaryngology, International Medical and Welfare University Hospital Surgery (biopsy may be performed at other medical facilities or other departments such as department of endoscopy).
(3)
a. Even if there is a history of invasive cancer that has developed in a different organ, the patient is included if a series of treatments has been completed and the patient has been in remission for at least 5 years.
b. Even if there is a history of invasive cancer that has developed in the same organ, the patient is included if a series of treatments has been completed and the patient has been in remission for at least 5 years.
c. If the history of cancer was carcinoma in situ, even if it has not been more than 5 years since the completion of a series of treatments, the patient is included in the trial.
(4) Even if a pathological sample for p53 staining evaluation cannot be obtained, it will be the subject of research (= This case is not included in the subgroup analysis, but is included in the overall analysis).
(5) The age of the day when the informed consent is received is 20 years of age and older as well as to 90 years of age and younger.However, if the principal investigator or the research coordinator determines that the consent ability is insufficient due to comorbidities such as dementia, or if a substitute person is required for consent, the research subje

Exclusion Criteria

Postoperative pathological results were found, for example, carcinoma in situ, sarcoma, surgery could not remove all tumors macroscopically (Patients who are histologically positive for tumor tissue stump are not excluded). Even if the patient is provisionally registered once, he/she can be excluded if it is before the start of supplementation (= randomization = main registration).

(1) Exclude cases that have undergone surgery at medical facilities other than the Department of Surgery and Otorhinolaryngology, Jikei University Hospital, and Surgery, or International University of Health and Welfare Hospital for the cancer type to be studied.
However, the following cases are included in the research target.
a. When only biopsy is performed in other facilities or department of endoscopy.
b. Endoscopic submucosal dissection (ESD) was performed at other facilities or department of endoscopy, and since it was Stage I or higher, Department of Surgery and Otorhinolaryngology, Jikei University Hospital, and Surgery, or International University of Health and Welfare Hospital is requested a complementary operation.
(2)
a. If there is a history of invasive cancer in a different organ and has not completed a series of treatments for more than 5 years, the patient is excluded from the trial.
b. If there is a history of invasive cancer in the same organ and has not completed a series of treatments for more than 5 years, the patient is excluded from the trial.
(3) Double cancer status (eg, esophageal cancer and head and neck cancer were found at the same time). However, if the double cancer is carcinoma in situ, it is included in the target.
(4) Participating in other clinical trials such as JCOG study, and not permitting it to participate in other clinical trials (if permitted, it is the subject of this study).
(5) Cancer that develops at another site after enrollment in this study is not considered as an outcome, but as an adverse event. For example, if a person is enrolled in this study as patients with colorectal cancer but develops gastric cancer one year later, the incidence of gastric cancer is not an outcome but an adverse event. Even if gastric cancer recurs later, it is not included in the outcome unless colorectal cancer recurs. This case is also counted as an adverse event.
(6) If participants have hypercalcemia (serum calcium level is 10.5 mg / dl or more) either at the time of main registration or at the time of provisional registration.
(7) If you have been taking vitamin D supplements for 500 IU / day or more for the past year or more and do not want to stop and switch to test supplements (intention) or for medical reasons. However, it is not necessary to exclude the following cases, but it should be stated in the case report form.
a. Vitamin D supplements tolerate less than 500 IU / day, such as 400 IU / day per day. Microgram x 40 = IU (International Unit), Example: 10microgram = 400 IU
b. Include patients taking active form of vitamin D (1,25-vitamin D), bisphosphonate, and/or calcium to prevent and/or treat osteoporosis.
(8) Preoperative diagnosis and postoperative pathological diagnosis are different, and if the main tumor is sarcoma, hematological malignancies such as malignant lymphoma, or neuroendocrine tumor (including carcinoid syndrome), other rare cancers (shown in the target diseases).
(9) Exclude cases where carcinoma in situ is diagnosed in the pathological tissue (= cancer with a near zero possibili

Study & Design

• Study Type: Interventional
• Study Design: Not specified